NCT05462574 Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
| NCT ID | NCT05462574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Idiopathic Pulmonary Arterial Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2023-01-17 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2023-01-17 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.
Eligibility Criteria
Inclusion criteria: * ≥ 18 years old * Diagnosed with idiopathic, heritable, connective tissue disease-associated PAH, associated pulmonary arterial hypertension (PAH), or drug-or toxin-associated PAH according to World Health Organization (WHO) consensus recommendations. * Stable PAH-specific medication regimen for three months prior to enrollment. Adjustments in IV prostacyclin for side effect management are allowed. Diuretic adjustments are permitted. * WHO Functional Class I-III * Ambulatory * Able to have an MRI/MRS, perform a 6MWD test, and cardiopulmonary exercise test Exclusion criteria: * Pregnancy * Diagnosis of PAH etiology other than idiopathic, heritable, connective tissue disease - associated PAH or associated with drugs and toxins * WHO Functional class IV heart failure * Requirement for continuous oxygen * Unable to have an MRI/MRS, perform a 6MWD test, or cardiopulmonary exercise test. * Patients with implanted/embedded ferromagnetic material that would preclude cardiac MRI
Contact & Investigator
Evan Brittain, MD, MSCI
PRINCIPAL INVESTIGATOR
Vanderbilt University Medical Center
Frequently Asked Questions
Who can join the NCT05462574 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Idiopathic Pulmonary Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05462574 currently recruiting?
Yes, NCT05462574 is actively recruiting participants. Contact the research team at natasha.billard.1@vumc.org for enrollment information.
Where is the NCT05462574 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT05462574 clinical trial?
NCT05462574 is sponsored by Vanderbilt University Medical Center. The principal investigator is Evan Brittain, MD, MSCI at Vanderbilt University Medical Center. The trial plans to enroll 75 participants.